SARS-CoV-2 Lineage A.27: New Data from African Countries and Dynamics in the Context of the COVID-19 Pandemic.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
09 05 2022
Historique:
received: 06 04 2022
revised: 05 05 2022
accepted: 05 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

SARS-CoV-2 is constantly evolving with lineages emerging and others eclipsing. Some lineages have an important epidemiological impact and are known as variants of interest (VOIs), variants under monitoring (VUMs) or variants of concern (VOCs). Lineage A.27 was first defined as a VUM since it holds mutations of concern. Here, we report additional lineage A.27 data and sequences from five African countries and describe the molecular characteristics, and the genetic history of this lineage worldwide. Based on the new sequences investigated, the most recent ancestor (tMRCA) of lineage A.27 was estimated to be from April 2020 from Niger. It then spread to Europe and other parts of the world with a peak observed between February and April 2021. The detection rate of A.27 then decreased with only a few cases reported during summer 2021. The phylogenetic analysis revealed many sub-lineages. Among them, one was defined by the substitution Q677H in the spike (S) gene, one was defined by the substitution D358N in the nucleoprotein (N) gene and one was defined by the substitution A2143V in the ORF1b gene. This work highlights the importance of molecular characterization and the timely submission of sequences to correctly describe the circulation of particular strains in order to be proactive in monitoring the pandemic.

Identifiants

pubmed: 35632749
pii: v14051007
doi: 10.3390/v14051007
pmc: PMC9144831
pii:
doi:

Substances chimiques

Coronavirus Nucleocapsid Proteins 0
Phosphoproteins 0
Spike Glycoprotein, Coronavirus 0
nucleocapsid phosphoprotein, SARS-CoV-2 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Commun. 2022 Mar 3;13(1):1152
pubmed: 35241661
PLoS One. 2021 Feb 17;16(2):e0247115
pubmed: 33596239
Cell. 2021 Jun 24;184(13):3426-3437.e8
pubmed: 33991487
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
Cell Rep Med. 2022 Mar 11;3(4):100583
pubmed: 35480627
Microbiol Spectr. 2021 Dec 22;9(3):e0063921
pubmed: 34756072
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
BMJ. 2020 Dec 16;371:m4857
pubmed: 33328153
medRxiv. 2021 Feb 21;:
pubmed: 33594385
Viruses. 2021 Jul 29;13(8):
pubmed: 34452356
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
PLoS Pathog. 2021 Jan 25;17(1):e1009246
pubmed: 33493182
Emerg Infect Dis. 2021 May;27(5):1540-1543
pubmed: 33900195
Clin Microbiol Infect. 2021 Sep;27(9):1352.e1-1352.e5
pubmed: 33991677
BMC Bioinformatics. 2014 Nov 19;15:366
pubmed: 25408143
Cell. 2021 May 13;184(10):2595-2604.e13
pubmed: 33891875
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Life Sci Alliance. 2020 Jul 23;3(9):
pubmed: 32703818

Auteurs

Anissa Chouikha (A)

Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, University Tunis El Manar (UTM), Tunis 1002, Tunisia.
Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Pasteur Institute, Tunis 1002, Tunisia.

Adamou Lagare (A)

Centre de Recherche Médicale et Sanitaire (CERMES), BP: 10887-634 Bd de la Nation, Niamey YN034, Niger.

Kais Ghedira (K)

Laboratory of Bioinformatics, Biomathematics and Biostatistics (BIMS), Institut Pasteur de Tunis (IPT), 13, Place Pasteur BP 74, University of Tunis-El Manar, Tunis 1002, Tunisia.

Amadou Diallo (A)

Institut Pasteur Dakar, 36 Avenue Pasteur, Dakar BP 220, Senegal.

Richard Njouom (R)

Centre Pasteur of Cameroon, Centre Pasteur of Cameroon, 451 rue 2005, Yaoundé, Cameroon.

Safietou Sankhe (S)

Institut Pasteur Dakar, 36 Avenue Pasteur, Dakar BP 220, Senegal.

Fawzi Derrar (F)

Institut Pasteur d'Algérie, 01 Rue du Petite Staouéli, Dély-Brahim, Algiers 16047, Algeria.

Kathleen Victoir (K)

Institut Pasteur, Direction Internationale, Pôle Coopération Scientifique, 25 Rue du Dr Roux, 75015 Paris, France.

Koussay Dellagi (K)

Pasteur Network Association, Institut Pasteur 25 Rue du Dr Roux, 75015 Paris, France.

Henda Triki (H)

Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, University Tunis El Manar (UTM), Tunis 1002, Tunisia.
Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Pasteur Institute, Tunis 1002, Tunisia.

Moussa Moise Diagne (MM)

Institut Pasteur Dakar, 36 Avenue Pasteur, Dakar BP 220, Senegal.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH